A recent pharmacovigilance study conducted using the FDA’s adverse event reporting system (FAERS) database revealed that canagliflozin had a significant association among SGLT2 inhibitors with acute kidney injury. This evidence concerns the gene SLC5A2 and acute kidney injury.